SUPERNUS PHARMACEUTICALS, INC. Defined Contribution Plan, Cost
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Defined Contribution Plan, Cost of $3.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-04-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2022-04-13
- SUPERNUS PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2021 was $3.00M, a 15.38% increase from fiscal 2020.
- SUPERNUS PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2020 was $2.60M, a 13.04% increase from fiscal 2019.
- SUPERNUS PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2019 was $2.30M, a 9.52% increase from fiscal 2018.
- SUPERNUS PHARMACEUTICALS, INC. defined contribution plan, cost for fiscal 2018 was $2.10M, a 16.67% increase from fiscal 2017.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2021-12-31 | $3.00M 10-K · filed 2022-04-13 | |
| 2020-12-31 | $2.60M 10-K · filed 2022-04-13 | |
| 2019-12-31 | $2.30M 10-K · filed 2022-04-13 | |
| 2018-12-31 | $2.10M 10-K · filed 2021-03-08 | |
| 2017-12-31 | $1.80M 10-K · filed 2020-02-28 | |
| 2016-12-31 | $1.60M 10-K · filed 2019-03-01 | |
| 2015-12-31 | $1.40M 10-K · filed 2018-03-01 | |
| 2014-12-31 | $1.10M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $600.00K 10-K/A · filed 2017-01-20 | $645.00K 10-K · filed 2014-03-21 |
| 2012-12-31 | $300.00K 10-K · filed 2015-03-12 | $323.00K 10-K · filed 2013-03-15 |
| 2011-12-31 | $267.00K 10-K · filed 2014-03-21 | |
| 2010-12-31 | $254.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |